Searchable abstracts of presentations at key conferences in endocrinology

ea0063p464 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

EGFR and IGF1R affect Sunitinib activity: novel targets for Broncho-Pulmonary Neuroendocrine Neoplasm treatment

Bresciani Giulia , Ditsiou Angeliki , Cilibrasi Chiara , Vella Viviana , Rea Federico , Schiavon Marco , Cavallesco Narciso Giorgio , Giamas Georgios , Zatelli Maria Chiara , Gagliano Teresa

Background: Available medical treatments for Broncho-Pulmonary Neuroendocrine Neoplasm (BP-NENs) derived from clinical trials are not specific for the management of this malignancy. Sunitinib, a multi-receptor tyrosine-kinases (RTKs) inhibitor, mainly described as VEGFR inhibitor, has shown its efficacy in Pancreatic NENs but there are not available data about its action in BP-NENs. Our aim was to understand the effects of RTKs inhibition promoted by Sunitinib in order to eval...

ea0032p519 | Endocrine tumours and neoplasia | ECE2013

mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids

Gagliano Teresa , Bellio Mariaenrica , Gentilin Erica , Mole Daniela , Tagliati Federico , Schiavon Marco , Cavallesco Narciso Giorgio , Calabrese Fiorella , Ambrosio Maria Rosaria , Rea Federico , Uberti Ettore degli , Zatelli Maria Chiara

Background: Bronchial carcinoids (BCs) are rare neuroendocrine tumors that are still orphan of medical treatment. Human BC primary cultures may display resistance to everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), in terms of cell viability reduction.Aim: To assess whether the novel dual PI3K/mTOR inhibitor, NVP-BEZ235, may be effective in everolimus-resistant human BC tissues and cell lines. In addition, we search for possible mark...